Menu
 
Research menu
Jump to menu

Publications:  Dr Louisa Chard

Lu S, Zhang Z, Du P, Chard LS, Yan W, Khouri ME, Wang Z, Zhang Z et al.(2020). A virus-infected, reprogrammed somatic cell–derived tumor cell (VIREST) vaccination regime can prevent initiation and progression of pancreatic cancer. Clinical Cancer Research vol. 26, (2) 465-476.
10.1158/1078-0432.CCR-19-1395
Miao J, Chard LS, Wang Z, Wang Y(2019). Syrian Hamster as an Animal Model for the Study on Infectious Diseases. Frontiers in Immunology vol. 10,
10.3389/fimmu.2019.02329
Wang P, Li X, Wang J, Gao D, Li Y, Li H, Chu Y, Zhang Z et al.(2018). Erratum: Author Correction: Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent (Nature communications (2017) 8 1 (1395)). Nature communications vol. 9, (1)
10.1038/s41467-017-02205-9
https://qmro.qmul.ac.uk/xmlui/handle/123456789/40043
Wang P, Li X, Wang J, Gao D, Li Y, Li H, Chu Y, Zhang Z et al.(2017). Re-designing Interleukin-12 to enhance its safety and potential as an anti-tumor immunotherapeutic agent. Nat Commun vol. 8, (1) 1395-1395.
10.1038/s41467-017-01385-8
https://qmro.qmul.ac.uk/xmlui/handle/123456789/33983
Yuan M, Wang P, Chard LS, Lemoine NR, Wang Y(2016). A simple and efficient approach to construct mutant vaccinia virus vectors. Journal of Visualized Experiments vol. 2016, (116)
10.3791/54171
Ahmed J, Yuan M, Li Y, Chu Y, Zhang Z, Gao D, Chard LS, Alusi G et al. (2015). A Promising Neo-Adjuvant Immuno-Therapeutic Agent for Preventing Cancer Recurrence and Metastasis After Surgery. MOLECULAR THERAPY. vol. 23, S166-S166.
10.1016/S1525-0016(16)34029-1
Yuan M, Gao X, Chard LS, Ali Z, Ahmed J, Li Y, Liu P, Lemoine NR et al.(2015). A marker-free system for highly efficient construction of vaccinia virus vectors using CRISPR Cas9. Molecular Therapy - Methods and Clinical Development vol. 2,
10.1038/mtm.2015.35
Chard LS, Maniati E, Wang P, Zhang Z, Gao D, Wang J, Cao F, Ahmed J et al.(2015). A vaccinia virus armed with interleukin-10 Is a promising therapeutic agent for treatment of murine pancreatic cancer. Clinical Cancer Research vol. 21, (2) 405-416.
10.1158/1078-0432.CCR-14-0464
Yuan M, Zhang W, Wang J, Al Yaghchi C, Ahmed J, Chard L, Lemoine NR, Wang Y(2015). Efficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system. Journal of Virology vol. 89, (9) 5176-5179.
10.1128/JVI.00339-15
https://qmro.qmul.ac.uk/xmlui/handle/123456789/6978
Chard LS, Lemoine NR, Wang Y(2015). New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer. OncoImmunology vol. 4, (9) 1-3.
10.1080/2162402X.2015.1038689
Ahmed J, Yuan M, Li Y, Chu Y, Shi H, Chard L, Alusi G, Lemoine N et al. (2014). A Novel Tumour Selective Oncolytic Vaccinia Virus Lacking the N1L Gene Enhances the Anti-Tumour Immune Response When Used as an Anticancer Therapeutic. MOLECULAR THERAPY. vol. 22, S248-S249.
Chard LS, Maniati E, Wang P, Hughes J, Wang J, Denes B, Fodor I, Hagemann T et al. (2013). A Vaccinia Virus Armed with Interleukin-10 That Dampens Host Immunity to the Vctor but Not to Tumor Is a Promising Therapeutic Agent for Pancreatic Cancer. MOLECULAR THERAPY. vol. 21, S196-S196.
Hiley CT, Chard LS, Gangeswaran R, Tysome JR, Briat A, Lemoine NR, Wang Y(2013). Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway. J Virol vol. 87, (5) 2781-2790.
10.1128/JVI.00854-12
Tysome JR, Li X, Wang S, Wang P, Gao D, Du P, Chen D, Gangeswaran R et al.(2012). A novel therapeutic regimen to eradicate established solid tumors with an effective induction of tumor-specific immunity. Clin Cancer Res vol. 18, (24) 6679-6689.
10.1158/1078-0432.CCR-12-0979
Wang P, Jiang G, Chard L, Wang J, Gao D, Cao H, Lemoine NR, Wang Y (2012). A Rationally Designed Oncolytic Adenovirus, Ad-TD-IL-12, Cures Pancreatic Cancer in the Immunocompetent Syrian Hamster. MOLECULAR THERAPY. vol. 20, S131-S131.
Hiley CT, Chard L, Lemoine N, Wang Y(2011). A novel replication-selective vaccinia virus vector to express diagnostic or therapeutic genes in hypoxic environments. HUMAN GENE THERAPY vol. 22, (10) A99-A100.
Chard LS, Bailey DS, Dash P, Banyard AC, Barrett T(2008). Full genome sequences of two virulent strains of peste-des-petits ruminants virus, the Côte d'Ivoire 1989 and Nigeria 1976 strains. Virus Res vol. 136, (1-2) 192-197.
10.1016/j.virusres.2008.04.018
Bailey D, Chard LS, Dash P, Barrett T, Banyard AC(2007). Reverse genetics for peste-des-petits-ruminants virus (PPRV): promoter and protein specificities. Virus Res vol. 126, (1-2) 250-255.
10.1016/j.virusres.2007.01.015
Bordeleau M-E, Mori A, Oberer M, Lindqvist L, Chard LS, Higa T, Belsham GJ, Wagner G et al.(2006). Functional characterization of IRESes by an inhibitor of the RNA helicase eIF4A. Nat Chem Biol vol. 2, (4) 213-220.
10.1038/nchembio776
Chard LS, Bordeleau M-E, Pelletier J, Tanaka J, Belsham GJ(2006). Hepatitis C virus-related internal ribosome entry sites are found in multiple genera of the family Picornaviridae. J Gen Virol vol. 87, (Pt 4) 927-936.
10.1099/vir.0.81546-0
Chard LS, Kaku Y, Jones B, Nayak A, Belsham GJ(2006). Functional analyses of RNA structures shared between the internal ribosome entry sites of hepatitis C virus and the picornavirus porcine teschovirus 1 Talfan. J Virol vol. 80, (3) 1271-1279.
10.1128/JVI.80.3.1271-1279.2006
Pisarev AV, Chard LS, Kaku Y, Johns HL, Shatsky IN, Belsham GJ(2004). Functional and structural similarities between the internal ribosome entry sites of hepatitis C virus and porcine teschovirus, a picornavirus. J Virol vol. 78, (9) 4487-4497.
10.1128/jvi.78.9.4487-4497.2004
Kaku Y, Chard LS, Inoue T, Belsham GJ(2002). Unique characteristics of a picornavirus internal ribosome entry site from the porcine teschovirus-1 talfan. J Virol vol. 76, (22) 11721-11728.
10.1128/jvi.76.22.11721-11728.2002
Return to top